MedTrace Logo

Bioavailability Study of MGL-3196 Tablets Compared to Capsules

NCT03413124 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2019-09-18

No results posted yet for this study

Summary

The purpose of this study is to compare the pharmacokinetics of MGL-3196 capsules with MGL-3196 tablets in healthy male subjects and female subjects not of child-bearing potential.

Conditions

  • Healthy

Interventions

DRUG

MGL-3196 Tablet

MGL-3196 in Tablet form

DRUG

MGL-3196 Capsule

MGL-3196 in Capsule form

Sponsors & Collaborators

  • Celerion

    collaborator INDUSTRY

  • Madrigal Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Terry O'Reilly, MD · Celerion

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-02-05
Primary Completion
2018-02-17
Completion
2018-03-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03413124 on ClinicalTrials.gov